Akero Therapeutics Inc (AKRO)

NASDAQ
22.37
-0.60(-2.61%)
  • Volume:
    93,299
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    21.91 - 23.11

AKRO Overview

Prev. Close
22.97
Day's Range
21.91-23.11
Revenue
-
Open
23.11
52 wk Range
21.34-38.26
EPS
-2.49
Volume
93,299
Market Cap
779.06M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-37.51%
Shares Outstanding
34,826,078
Next Earnings Date
Nov 17, 2021
What is your sentiment on Akero Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Akero Therapeutics Inc News

Akero Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Akero Therapeutics Inc Company Profile

Akero Therapeutics Inc Company Profile

Employees
21

Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.